UBS lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $5 from $12 and keeps a Buy rating on the shares. UBS is optimistic on second half of 2025 PKP2 read-out, but is cautiously optimistic on possible recovery of the Danon program as Rocket seems to have isolated the root cause for patient death, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Optimistic Buy Rating for Rocket Pharmaceuticals Despite Gene Therapy Concerns
- Rocket Pharmaceuticals Faces Legal Storm Over Trial Omission
- Rocket Pharmaceuticals price target lowered to $11 from $34 at Canaccord
- Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts
- Rocket Pharmaceuticals downgraded at Evercore following patient death in study